On April 1, 2026, Syndax Pharmaceuticals (Nasdaq: SNDX) awarded inducement stock options to eight new employees under the 2023 Inducement Plan. The award allows them to purchase up to 228,500 shares of common stock. These options will vest over four years, with 25% of the shares vesting after one year, and the remaining shares vesting monthly over the following 36 months, contingent upon the employees' continued service with Syndax.